Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THC versus CBD versus placebo effects on psychosis-like measures and multisensory perception in healthy volunteers
ACTRN12621000469819Phase 3Not yet recruiting
- Sponsor
- The University of Western Australia
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dronabinol and cannabidiol in schizophrenia and Schizophrenia Spectrum Disorders (SSD), sponsored by The University of Western Australia. Planned start May 2021; status: not yet recruiting.
02
Drugs
dronabinolcannabidiol
03
Conditions
schizophreniaSchizophrenia Spectrum Disorders (SSD)
Beyond the preview
Go deeper on ACTRN12621000469819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000469819.